- Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder
Branka Petković et al, 2020, Current Pharmaceutical Design CrossRef - Gender, homelessness, hospitalization and methamphetamine use fuel depression among people who inject drugs: implications for innovative prevention and care strategies
Lionel Moulis et al, 2023, Frontiers in Psychiatry CrossRef - Distribution of hepatitis С virus drug resistance mutations among patients with recurrence of the disease during therapy with direct antiviral drugs
D. E. Reingardt et al, 2024, HIV Infection and Immunosuppressive Disorders CrossRef - Neurological Consequences of SARS-CoV-2 Infection and Concurrence of Treatment-Induced Neuropsychiatric Adverse Events in COVID-19 Patients: Navigating the Uncharted
Pobitra Borah et al, 2021, Frontiers in Molecular Biosciences CrossRef - Two Cases of Chronic Central Serous Chorioretinopathy Successfully Treated with Systemic Interferon Alpha
Lingling Huang et al, 2024, Ocular Immunology and Inflammation CrossRef - Viral hepatitis: A brief introduction, review of management, advances and challenges
Olga Fagan et al, 2021, World Journal of Meta-Analysis CrossRef - Neuropsychiatric Effects of Antiviral Drugs
Nicholas Zareifopoulos et al, 2020, Cureus CrossRef - COVID-19, interferons, and depression: A commentary
Richard I. Shader, 2020, Psychiatry Research CrossRef - Safety of Interferon Products: a Retrospective Analysis of Adverse Reactions Spontaneously Reported in the Republic of Crimea
Alexander V. Matveev et al, 2021, Health, Food & Biotechnology CrossRef - Research progress on pathogenic and therapeutic mechanisms of Enterovirus A71
Jianmei Lai et al, 2023, Archives of Virology CrossRef - Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
Dorota Dybowska et al, 2023, World Journal of Gastroenterology CrossRef